Michael G Goggins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4447859/publications.pdf

Version: 2024-02-01

164 papers	27,490 citations	12330 69 h-index	6131 159 g-index
170 all docs	170 docs citations	170 times ranked	27062 citing authors

#	Article	IF	Citations
1	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
2	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	13.7	2,155
3	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
4	Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
5	Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
6	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut, 2013, 62, 339-347.	12.1	672
7	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. American Journal of Surgical Pathology, 2015, 39, 1730-1741.	3.7	626
8	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 2009, 41, 986-990.	21.4	597
9	Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds. Cancer Research, 2004, 64, 2634-2638.	0.9	595
10	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
11	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.3	570
12	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
13	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics, 2010, 42, 224-228.	21.4	539
14	Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clinical Gastroenterology and Hepatology, 2006, 4, 766-781.	4.4	493
15	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
16	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
17	Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clinical Gastroenterology and Hepatology, 2004, 2, 606-621.	4.4	431
18	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	1.3	376

#	Article	IF	Citations
19	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
20	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 3382-3390.	1.6	316
21	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
22	Targeted nextâ€generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Journal of Pathology, 2014, 233, 217-227.	4.5	308
23	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
24	Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology, 2018, 155, 740-751.e2.	1.3	288
25	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
26	A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas, 2014, 43, 331-337.	1.1	276
27	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. American Journal of Surgical Pathology, 2006, 30, 1067-76.	3.7	261
28	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
29	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine, 2015, 17, 569-577.	2.4	231
30	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
31	Molecular Markers of Early Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4524-4531.	1.6	212
32	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. Cancer Research, 2014, 74, 3381-3389.	0.9	207
33	Overexpression of S100A4 in Pancreatic Ductal Adenocarcinomas Is Associated with Poor Differentiation and DNA Hypomethylation. American Journal of Pathology, 2002, 160, 45-50.	3.8	203
34	MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias. Clinical Cancer Research, 2012, 18, 981-992.	7.0	198
35	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clinical Cancer Research, 2009, 15, 7737-7743.	7.0	195
36	Importance of Age of Onset in Pancreatic Cancer Kindreds. Journal of the National Cancer Institute, 2010, 102, 119-126.	6.3	193

#	Article	IF	Citations
37	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2004, 164, 903-914.	3.8	190
38	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
39	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell, 2015, 161, 1345-1360.	28.9	175
40	Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Medicine, 2014, 6, 61.	8.2	170
41	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science, 2019, 364, 1156-1162.	12.6	166
42	MutantGNASdetected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
43	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgical Oncology, 2013, 20, 3802-3808.	1.5	158
44	Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut, 2015, 64, 1783-1789.	12.1	157
45	Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2011, 17, 4341-4354.	7.0	154
46	Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. International Journal of Epidemiology, 2018, 47, 427-439.	1.9	141
47	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 153-164.	1.6	135
48	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut, 2017, 66, 1677-1687.	12.1	134
49	Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 704-710.	2.5	133
50	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	4.2	131
51	Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 6544-6555.	7.0	129
52	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
53	An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic Cancer in the General Population. PLoS ONE, 2013, 8, e72311.	2.5	120
54	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	7.0	118

#	Article	IF	Citations
55	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. Journal of the National Cancer Institute, 2020, 112, 1162-1169.	6.3	114
56	Genetic analyses of isolated highâ€grade pancreatic intraepithelial neoplasia (HGâ€PanIN) reveal paucity of alterations in TP53 and SMAD4. Journal of Pathology, 2017, 242, 16-23.	4.5	108
57	Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Science, 2016, 107, 569-575.	3.9	106
58	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgery, 2017, 266, 133-141.	4.2	106
59	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
60	IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut, 2018, 67, 1652-1662.	12.1	104
61	Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene, 2004, 23, 9042-9051.	5.9	103
62	Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell, 2017, 32, 824-839.e8.	16.8	97
63	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 2681-2690.	7.0	91
64	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
65	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. Seminars in Oncology, 2007, 34, 303-310.	2.2	89
66	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
67	Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biology and Therapy, 2005, 4, 728-733.	3.4	83
68	The Gut Microbiome in Pancreatic Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 290-295.	4.4	76
69	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
70	Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2012, 18, 700-712.	7.0	69
71	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	1.6	69
72	Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	7.1	65

#	Article	IF	Citations
73	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. Journal of Clinical Oncology, 2019, 37, 1070-1080.	1.6	65
74	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	2.2	64
75	Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2104-2111.	1.5	64
76	Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clinical Cancer Research, 2017, 23, 3935-3944.	7.0	63
77	Can we screen high-risk individuals to detect early pancreatic carcinoma?. Journal of Surgical Oncology, 2000, 74, 243-248.	1.7	62
78	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2018, 226, 630-637e1.	0.5	62
79	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.3	60
80	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
81	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Research, 2020, 80, 2804-2817.	0.9	58
82	Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clinical Cancer Research, 2018, 24, 2963-2974.	7.0	55
83	Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1101-1110.	1.7	55
84	Pancreatic cancerDNMT1expression and sensitivity toDNMT1inhibitors. Cancer Biology and Therapy, 2010, 9, 321-329.	3.4	54
85	Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology, 2019, 156, 2041-2055.	1.3	52
86	Singleâ€cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Journal of Pathology, 2019, 247, 347-356.	4.5	52
87	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	7.1	50
88	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1238-1245.	2.5	48
89	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology, 2019, 156, 1905-1913.	1.3	47
90	Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. Annals of Surgical Oncology, 2014, 21, 3668-3674.	1.5	45

#	Article	IF	Citations
91	Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer, 2006, 107, 251-257.	4.1	43
92	Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointestinal Endoscopy, 2015, 82, 812-818.	1.0	43
93	Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. Clinical Cancer Research, 2016, 22, 5141-5151.	7.0	43
94	Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2022, 20, e196-e227.	4.4	41
95	Tumor-Suppressor genes in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 383-391.	2.0	40
96	Markers of Pancreatic Cancer: Working Toward Early Detection. Clinical Cancer Research, 2011, 17, 635-637.	7.0	39
97	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	2.8	39
98	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. JAMA Oncology, 2021, 7, 1664.	7.1	39
99	Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clinical Cancer Research, 2014, 20, 6200-6211.	7.0	38
100	Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biology and Therapy, 2004, 3, 651-656.	3.4	35
101	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	4.4	34
102	A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology, 2015, 15, 387-391.	1.1	32
103	Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. American Journal of Pathology, 2018, 188, 1723-1733.	3.8	32
104	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 1161-1169.e5.	4.4	31
105	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
106	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. PLoS ONE, 2015, 10, e0117574.	2.5	29
107	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	0.9	29
108	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29

#	Article	IF	Citations
109	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clinical and Translational Gastroenterology, 2014, 5, e62.	2.5	28
110	Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements. Pancreatology, 2021, 21, 613-621.	1.1	27
111	Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms. Cancer Biology and Therapy, 2005, 4, 596-601.	3.4	24
112	Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2â€²-Deoxycytidine. PLoS ONE, 2012, 7, e43456.	2.5	24
113	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	2.6	24
114	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	4.5	23
115	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology, 2020, 33, 2544-2563.	5.5	23
116	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Modern Pathology, 2019, 32, 1806-1813.	5.5	21
117	Follow-up of Incidentally Detected Pancreatic Cystic Neoplasms: Do Baseline MRI and CT Features Predict Cyst Growth?. Radiology, 2019, 292, 647-654.	7.3	20
118	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Modern Pathology, 2019, 32, 659-665.	5.5	20
119	Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. European Journal of Radiology, 2015, 84, 575-580.	2.6	19
120	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Letters, 2020, 493, 245-253.	7.2	18
121	Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
122	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	3.0	16
123	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	2.8	16
124	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surgical Oncology Clinics of North America, 2021, 30, 773-786.	1.5	16
125	Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4293-4303.	3.6	15
126	Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2016, 11, e0164195.	2.5	15

#	Article	IF	Citations
127	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15
128	Urine DNA biomarkers for hepatocellular carcinoma screening. British Journal of Cancer, 2022, 126, 1432-1438.	6.4	15
129	In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Laboratory Investigation, 2010, 90, 665-673.	3.7	14
130	Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2379-2386.	1.5	14
131	IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Oncotarget, 2017, 8, 83370-83383.	1.8	14
132	Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements. Journal of Molecular Diagnostics, 2019, 21, 658-676.	2.8	13
133	Downregulation of 5â€hydroxymethylcytosine is an early event in pancreatic tumorigenesis. Journal of Pathology, 2021, 254, 279-288.	4.5	12
134	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2020, 231, 527-535.e14.	0.5	11
135	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Journal of Molecular Diagnostics, 2020, 22, 748-756.	2.8	11
136	Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Oncotarget, 2017, 8, 50824-50831.	1.8	11
137	Endoplasmic stressâ€inducing variants in <scp>CPB1</scp> and <scp>CPA1</scp> and risk of pancreatic cancer: A caseâ€control study and metaâ€analysis. International Journal of Cancer, 2022, 150, 1123-1133.	5.1	11
138	BRCA2 and predisposition to pancreatic and other cancers. Expert Reviews in Molecular Medicine, 2001, 3, 1-10.	3.9	10
139	Using an endoscopic distal cap to collect pancreatic fluid fromÂthe ampulla (with video). Gastrointestinal Endoscopy, 2017, 86, 1152-1156.e2.	1.0	10
140	Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1487-1500.	7.3	10
141	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	4.7	9
142	Classifying pancreatic cancer using gene expression profiling. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 613-614.	17.8	8
143	Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. Journal of Gastrointestinal Surgery, 2019, 23, 477-483.	1.7	8
144	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.9	8

#	Article	IF	Citations
145	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.1	8
146	Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2022, 20, 2267-2275.e2.	4.4	8
147	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
148	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	2.5	6
149	Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. Oncotarget, 2019, 10, 5592-5604.	1.8	6
150	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. ELife, 2022, 11, .	6.0	6
151	Pancreatic volume does not correlate with histologic fibrosis in adult patients with recurrent acute and chronic pancreatitis. Pancreatology, 2020, 20, 1078-1084.	1.1	5
152	Genome-Wide Geneâ€“Diabetes and Geneâ€“Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	2.5	5
153	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.9	5
154	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. British Journal of Cancer, 2021, 125, 1712-1717.	6.4	4
155	Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. Pancreatology, 2016, 16, 869-872.	1.1	3
156	Editorial: Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	3
157	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Laboratory Investigation, 2020, 100, 1003-1013.	3.7	3
158	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.5	3
159	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Pancreatology, 2021, 21, 938-941.	1.1	1
160	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	3.8	0
161	Bayesian copy number detection and association in large-scale studies. BMC Cancer, 2020, 20, 856.	2.6	0
162	Abstract 30: Impact of race, sex and age on the risk of pancreatic cancer in new onset diabetics in real-world data. , 2021, , .		0

#	Article	IF	Citations
163	Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 164-164.	1.6	0
164	Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay.. Journal of Clinical Oncology, 2012, 30, 151-151.	1.6	0